Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, Wang S. Xiang W, et al. Among authors: han x. J Med Chem. 2021 Sep 23;64(18):13487-13509. doi: 10.1021/acs.jmedchem.1c00900. Epub 2021 Sep 2. J Med Chem. 2021. PMID: 34473519 Free PMC article.
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, Yang CY, Wang M, Han X, Wang S. Li Y, et al. Among authors: han x. J Med Chem. 2019 Jan 24;62(2):448-466. doi: 10.1021/acs.jmedchem.8b00909. Epub 2018 Dec 10. J Med Chem. 2019. PMID: 30525597 Free PMC article.
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X, Zhao L, Xiang W, Miao B, Qin C, Wang M, Xu T, McEachern D, Lu J, Wang Y, Metwally H, Yang CY, Kirchhoff PD, Wang L, Matvekas A, Takyi-Williams J, Wen B, Sun D, Ator M, Mckean R, Wang S. Han X, et al. J Med Chem. 2023 Jul 13;66(13):8822-8843. doi: 10.1021/acs.jmedchem.3c00405. Epub 2023 Jun 29. J Med Chem. 2023. PMID: 37382562 Free PMC article.
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
Xiang W, Zhao L, Han X, Xu T, Kregel S, Wang M, Miao B, Qin C, Wang M, McEachern D, Lu J, Bai L, Yang CY, Kirchhoff PD, Takyi-Williams J, Wang L, Wen B, Sun D, Ator M, Mckean R, Chinnaiyan AM, Wang S. Xiang W, et al. Among authors: han x. J Med Chem. 2023 Sep 28;66(18):13280-13303. doi: 10.1021/acs.jmedchem.3c01264. Epub 2023 Sep 8. J Med Chem. 2023. PMID: 37683104
Corrigendum to 'Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment' Neoplasia, Volume 22, Issue 2 (2020) 111-119.
Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Kregel S, et al. Among authors: han x. Neoplasia. 2024 May;51:100986. doi: 10.1016/j.neo.2024.100986. Epub 2024 Mar 15. Neoplasia. 2024. PMID: 38492449 Free PMC article. No abstract available.
21,025 results
You have reached the last available page of results. Please see the User Guide for more information.